SOPHiA GENETICS Secures Additional $25M Term Loan Commitments and Issues New Warrants
SOPH has more than doubled off its 52-week low of $2.58.
Summary
SOPHiA GENETICS SA secured an additional $25 million in term loan commitments and issued warrants for 275,000 ordinary shares, providing crucial capital but with potential future dilution.
Key Events · Financing and Capital Events · SOPH
-
Additional Term Loan Commitments
The company secured an additional $25 million in term loan commitments from Perceptive Credit Holdings IV, LP, structured in two tranches (Tranche C and Tranche D).
-
New Warrants Issued
In connection with the loan amendment, SOPHiA GENETICS issued warrants for an additional 275,000 ordinary shares to the lender. 75,000 shares are immediately exercisable at $5.1829, with another 200,000 shares becoming exercisable upon drawdown of the new loan tranches at future VWAP-based prices.
-
Loan Terms and Conditions
The new term loans bear interest at Term SOFR + 6.25% and mature in 2029. The $12.5 million Tranche D loan is conditional on the company achieving over $85 million in trailing twelve-month revenue.
Analysis · SOPH · Technology
SOPHiA GENETICS SA has amended its credit agreement with Perceptive Credit Holdings IV, LP, securing an additional $25 million in term loan commitments. This capital infusion is crucial for the company's liquidity and operations, providing a longer financial runway. However, the terms include a relatively high interest rate (Term SOFR + 6.25%) and the issuance of warrants for 275,000 ordinary shares, which represent potential future dilution for existing shareholders. The availability of one tranche is contingent on achieving a significant revenue milestone, indicating performance-based access to a portion of the funds. While the financing addresses immediate capital needs, the cost of debt and potential dilution are notable considerations for investors.
At the time of this filing, SOPH was trading at $5.25 on NASDAQ in the Technology sector, with a market capitalization of approximately $356.2M. The 52-week trading range was $2.58 to $5.70. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.